口服促性腺激素释放激素拮抗剂治疗子宫内膜异位症相关疼痛:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入5项研究共6项随机对照试验、2796名绝经前子宫内膜异位症中重度疼痛女性,评估10种不同剂量口服GnRH拮抗剂的疗效与安全性。结果显示几乎所有疗效和安全性结局呈剂量-反应关系,口服GnRH拮抗剂对子宫内膜异位症相关疼痛、痛经及患者整体印象有效,但高剂量治疗与多数生活质量及不良事件结局显著相关。
要点
- 口服GnRH拮抗剂对子宫内膜异位症相关疼痛和痛经有效,疗效呈剂量-反应关系。
- 疼痛改善排名前3为艾拉戈利400mg、林扎戈利75mg和林扎戈利200mg。
- 瑞卢戈利40mg与20mg及艾拉戈利400mg的不良事件发生率显著增加。
核心结论
- 口服GnRH拮抗剂对子宫内膜异位症相关疼痛、痛经及患者整体印象有效。
- 短期卵巢低雌激素效应发生率呈剂量-效应关系,最高剂量尤为显著。
研究设计与样本
- 系统综述与网状Meta分析,检索Web of Science、Embase、Scopus和MEDLINE至2022年4月10日,仅纳入随机对照试验。
- 共纳入5项研究中的6项随机对照试验,合计2796名绝经前子宫内膜异位症中重度疼痛女性,涉及10种不同剂量的口服GnRH拮抗剂治疗。
- 采用Cochrane偏倚风险工具2评估偏倚风险,所有研究均被认为低偏倚风险。
- 采用贝叶斯随机效应网状Meta分析进行间接比较,使用I2评估全局异质性,通过累积排序曲线下面积进行治疗排序,采用GRADE框架评估证据确定性。
主要发现
- 子宫内膜异位症相关疼痛改善排名前3的治疗为艾拉戈利400mg、林扎戈利75mg和林扎戈利200mg,平均差分别为-1.26(95%可信区间[CrI],-1.70至-0.79)、-0.98(95%CrI,-1.84至-0.15)和-0.98(95%CrI,-1.90至-0.064)。
- 痛经改善排名前3的治疗为瑞卢戈利40mg、艾拉戈利400mg和瑞卢戈利20mg,平均差分别为-1.60(95%CrI,-2.07至-1.14)、-1.25(95%CrI,-1.56至-0.95)和-1.10(95%CrI,-1.59至-0.62)。
- 仅高剂量治疗与多数生活质量和不良事件相关结局显著相关。
- 瑞卢戈利40mg、瑞卢戈利20mg和艾拉戈利400mg的不良事件发生率显著增加,比值比分别为6.88(95%CrI,2.18-24.58)、1.60(95%CrI,0.62-4.13)和1.85(95%CrI,1.05-3.30)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review the use of oral gonadotropin-releasing hormone (GnRH) antagonists and synthesize their efficacy and safety parameters for the treatment of endometriosis-associated pain. DESIGN: Systematic review and network meta-analysis. SETTING: Not applicable. PATIENT(S): Premenopausal women with endometriosis who had experienced moderate or severe pain. INTERVENTION(S): The Web of Science, Embase, Scopus, and MEDLINE were searched until April 10, 2022. Only randomized controlled trials were included. The risk of bias in the included studies was assessed using the Cochrane Risk of Bias tool 2. A Bayesian random-effects network meta-analysis was used to perform indirect comparisons. I2 was used to assess the global heterogeneity. Relative treatment estimates were performed. Treatment ranking was performed through the surface under the cumulative ranking curve. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation framework. MAIN OUTCOME MEASURE(S): Endometriosis-associated pain, dysmenorrhea, dyspareunia, and noncyclic pelvic pain reduction. RESULT: (s): Five studies and 6 randomized controlled trials, including a total of 2,796 women and 10 different doses of oral GnRH antagonist treatments, were eligible for inclusion. All studies were considered to have a low risk of bias. Almost all efficacy- and safety-related outcomes showed a dose-response relationship. Regarding endometriosis-associated pain, the top 3 treatments were elagolix 400 mg, linzagolix 75 mg, and linzagolix 200 mg, with mean differences of -1.26 (95% credible interval [CrI], -1.70 to -0.79), -0.98 (95% CrI, -1.84 to -0.15), and -0.98 (95% CrI, -1.90 to -0.064), respectively. The top 3 treatments to decrease dysmenorrhea were relugolix 40 mg, elagolix 400 mg, and relugolix 20 mg, with mean differences of -1.60 (95% CrI, -2.07 to -1.14), -1.25 (95% CrI, -1.56 to -0.95), and -1.10 (95% CrI, -1.59 to -0.62), respectively. However, only high-dose treatments were significantly associated with most quality of life- and adverse effect-related outcomes. Relugolix 40 and 20 mg and elagolix 400 mg, with odds ratios of 6.88 (95% CrI, 2.18-24.58), 1.60 (95% CrI, 0.62-4.13), and 1.85 (95% CrI, 1.05-3.30), had a significantly increased incidence of adverse events. CONCLUSION: (s): Oral GnRH antagonists are effective for endometriosis-associated pain and dysmenorrhea and the patient global impression. The incidence of ovarian hypoestrogenic effects in a short-term duration was significant in a dose-effect response, particularly the highest dose. CLINICAL TRIAL REGISTRATION NUMBER: International Prospective Register of Systematic Reviews registration number CRD42022332904.
引用
- Yan H, Shi J, Li X, et al. Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis. Fertil Steril. 2022. PMID: 36283862. doi:10.1016/j.fertnstert.2022.08.856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。